Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: A meta-analysis

Osteoporosis International

Volumn 17, Issue 11, 2006, Pages 1630-1637

  Nevitt, M C ^a   Chen, P ^b   Kiel, D P ^c   Reginster, J Y ^d   Dore, R K ^e   Zanchetta, J R ^f   Glass, E V ^b   Krege, J H ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF LIÈGE   (Belgium)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Institute of Metabolic Investigations   (Argentina)

Author keywords

Back pain; Osteoporosis; rhPTH 1 34; Teriparatide

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; PARATHYROID HORMONE[1-34]; PLACEBO; VITAMIN D;

ARTICLE; BACKACHE; CLINICAL OBSERVATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; META ANALYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROPHYLAXIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

BACK PAIN; BONE DENSITY CONSERVATION AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPINAL FRACTURES; TERIPARATIDE;

EID: 33749177248     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-006-0177-z     Document Type: Article

References (20)

1. Riggs BL, Melton LJ III (1995) The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 17(5 Suppl):505S-511S
2. Nevitt MC, Ettinger B, Black DM et al (1998) The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 128 (10):793-800
3. Cooper C, Atkinson EJ, O'Fallon WM (1992) Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 7:221-227
4. Fink HA, Milavetz DL, Palermo L et al (2005) What proportion of incident radiographic vertebral deformities is clinically diagnosed and vice versa? J Bone Miner Res 20:1216-1222
5. Silverman SL, Piziak VK, Chen P et al (2005) Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. J Rheumatol 32(12):2405-2409
6. Genant HK, Halse J, Briney WG et al (2005) The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Curr Med Res Opin 21(7):1027-1034
7. Gold DT (1996) The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone 18(3 Suppl):185S-189S
8. Edmond SL, Kiel DP, Samelson EJ et al (2005) Vertebral deformity, back symptoms, and functional limitations among older women: the Framingham study. Osteoporos Int 6(9):1086-1095
9. Ismail AA, Cooper C, Felsenberg D et al (1999) Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. European vertebral osteoporosis study group. Osteoporos Int 9(3):206-213
10. Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19):1434-1441
11. Lindsay R, Scheele WH, Neer R et al (2004) Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 164 (18):2024-2030
12. Miller PD, Shergy WJ, Body JJ et al (2005) Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. J Rheumatol 32 (8):1556-1562
13. Nevitt MC, Chen P, Dore RK et al (2006) Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int 17(2):273-280
14. Orwoll ES, Scheele WH, Paul S et al (2003) The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18 (1):9-17
15. Body JJ, Gaich GA, Scheele WH et al (2002) A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87(10):4528-4535
16. Ste-Marie LG, Schwartz SL, Hossain AM et al (2006) Effect of teriparatide [rh parathyroid hormone (1-34)] on bone density when given to postmenopausal women receiving hormone replacement therapy. J Bone Miner Res 21(2):283-291
17. Kaufman JM, Orwoll E, Goemaere S et al (2005) Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 16(5):510-516
18. Gold DT (1996) The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone 18(suppl 3):185-189
19. Cooper C (1993) Epidemiology and public health impact of osteoporosis. Clin Rheumatol 7:459-477
20. Andersson GB (1999) Epidemiological features of chronic low-back pain. Lancet 354:581-585